Seattle Clinical Research Center is excited to announce that the FDA has approved Aimovig, a new treatment developed specifically for migraine headache prevention. Migraine is a debilitating condition that impacts 38 million patients in the United States. Seattle Clinical Research Center conducted one of the pivotal clinical trials involved in the approval process. Aimovig is the first medication in a new class of drugs that blocks a specific receptor, CGRP-R, which plays an important role in migraine headaches.
“Aimovig provides patients with a novel option for reducing the number of days with migraine,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We need new treatments for this painful and often debilitating condition.”
Migraine patients experience excruciating headache pain, often accompanied by nausea and vomiting. The condition may cause sufferers to miss work and school, as well as significantly decreasing quality of life.
Aimovig is given as a once-a-month self-injection that’s similar to an insulin pen.
Unlike current migraine medications that focus on treating symptoms, Aimovig is the first medication that is designed to prevent migraines before they start. It also seems to have fewer daily side effects than the medications that are currently on the market.
We are pleased to have participated in one of the clinical trial with this breakthrough, first in class drug. We continue to conduct trials on this class of drug, offering qualified subjects access to these medications through clinical trials. For information on our current studies, please call 206-522-3330 x 2.